Is atezolizumab plus bevacizumab as first-line therapy for unresectable hepatocellular carcinoma superior to lenvatinib? a systematic review and meta‑analysis.

Background: This meta-analysis was dedicated to evaluating the effectiveness and safety of Atezolizumab plus Bevacizumab (Atez/Bev) and Lenvatinib (LEN) as first-line systematic therapy for unresectable hepatocellular carcinoma (u-HCC). Methods: The prospective protocol for this study was registered...

Full description

Bibliographic Details

Published in:	European Journal of Clinical Pharmacology Vol. 80; no. 10; pp. 1425 - 1435
Main Authors:	Zhu, Gang, Zeng, Longfei, Yang, Liu, Zhang, Xin, Tang, Jinquan, Pan, Yong, Li, Bo, Chen, Mengchen, Wu, Tao
Format:	meta analysis research systematic review tables/charts Journal Article
Published:	Springer Nature Oct2024
Online Access:	View this record in EBSCOhost